Clinical Trial Update: Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Prochymal for salvage therapy in treatment-refractory acute graft-versus-host disease, reporting safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• PROCHYMAL (allogeneic mesenchymal stem cells)

Snippet

Sponsor: Mesoblast, Inc. | Conditions: Graft Versus Host Disease | Phase 2 | Status: COMPLETED